BlackRock
LTRN icon

BlackRock’s Lantern Pharma LTRN Stock Holding History

BlackRock’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.2K Sell
22,350
-22,917
-51% -$67.2K ﹤0.01% 5021
2026
Q1 		$62K Buy
45,267
+1,014
+2% +$2.83K ﹤0.01% 5074
2025
Q4 		$134K Buy
44,253
+1,163
+3% +$4.33K ﹤0.01% 4825
2025
Q3 		$187K Buy
43,090
+815
+2% +$3.4K ﹤0.01% 4687
2025
Q2 		$134K Buy
42,275
+2,027
+5% +$6.84K ﹤0.01% 4771
2025
Q1 		$142K Sell
40,248
-348
-0.9% -$1.44K ﹤0.01% 4675
2024
Q4 		$130K Buy
40,596
+116
+0.3% +$397 ﹤0.01% 4725
2024
Q3 		$149K Buy
40,480
+639
+2% +$2.63K ﹤0.01% 4594
2024
Q2 		$186K Buy
39,841
+20,182
+103% +$121K ﹤0.01% 4564
2024
Q1 		$173K Sell
19,659
-303
-2% -$1.62K ﹤0.01% 4624
2023
Q4 		$85.4K Sell
19,962
-186
-0.9% -$656 ﹤0.01% 4847
2023
Q3 		$68.7K Sell
20,148
-651
-3% -$2.96K ﹤0.01% 4941
2023
Q2 		$117K Sell
20,799
-651
-3% -$3.36K ﹤0.01% 4866
2023
Q1 		$104K Buy
21,450
+558
+3% +$2.93K ﹤0.01% 4945
2022
Q4 		$126K Buy
20,892
+372
+2% +$1.86K ﹤0.01% 4970
2022
Q3 		$98K Sell
20,520
-2,242
-10% -$12.1K ﹤0.01% 5180
2022
Q2 		$129K Sell
22,762
-312
-1% -$1.86K ﹤0.01% 5162
2022
Q1 		$164K Sell
23,074
-936
-4% -$6.25K ﹤0.01% 5159
2021
Q4 		$190K Buy
24,010
+936
+4% +$8.55K ﹤0.01% 5116
2021
Q3 		$258K Sell
23,074
-2,043
-8% -$26.4K ﹤0.01% 4927
2021
Q2 		$366K Buy
25,117
+1,467
+6% +$22.7K ﹤0.01% 4768
2021
Q1 		$429K Buy
23,650
+18,409
+351% +$323K ﹤0.01% 4629
2020
Q4 		$101K Buy
5,241
+232
+5% +$4.01K ﹤0.01% 4583
2020
Q3 		$94K Buy
+5,009
New +$72.5K ﹤0.01% 4525

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

BlackRock's LTRN Position: Q2 2026 in Review

BlackRock reduced its Lantern Pharma (LTRN) stake by 51% in Q2 2026, selling an estimated $67.2K and leaving 22,350 shares worth $93.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5021.

BlackRock first reported a position in LTRN in Q3 2020 and has held it in 24 quarters since. The position peaked at $429K in Q1 2021. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • BlackRock held 22,350 shares of Lantern Pharma worth $93.2K as of Q2 2026.
  • BlackRock sold 22,917 Lantern Pharma shares in Q2 2026, an estimated $67.2K.
  • Lantern Pharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5021 holding.
  • BlackRock first reported a position in Lantern Pharma in Q3 2020 and has held it in 24 quarters since.
  • BlackRock's Lantern Pharma position peaked at $429K in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.